Vadadustat
Vadadustat, sold under the brand name Vafseo is a medication used for the treatment of symptomatic anemia associated with chronic kidney disease.

The most common side effects include thromboembolic events (problems due to the formation of blood clots in the blood vessels), diarrhea, and hypertension (high blood pressure).

Vadadustat was approved for medical use in the European Union in April 2023.

Medical uses 
Vadadustat is indicated for the treatment of symptomatic anemia associated with chronic kidney disease in adults on chronic maintenance dialysis.

Society and culture

Legal status 
On 23 February 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vafseo, intended for the treatment of symptomatic anemia in adults with chronic kidney disease who are on chronic dialysis. The applicant for this medicinal product is Akebia Europe Limited. Vadadustat was approved for medical use in the European Union in April 2023.

Research 
Vadadustat is in phase III clinical trials for the treatment of anemia caused by chronic kidney disease.

References 

Acetic acids
Pyridines